Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson(National Cancer Institute), Owen A. O’Connor(NYU Langone Health), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Ann S. LaCasce(Dana-Farber Cancer Institute), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), John P. Leonard(Cornell University), Anil Tulpule, Kieron Dunleavy(National Cancer Institute), Hao Xiong(Abbott (United Kingdom)), Yi‐Lin Chiu(Abbott Fund), Yue Cui(Abbott (United Kingdom)), Todd Busman(Abbott Fund), Steven W. Elmore(Abbott Fund), Saul H. Rosenberg(Abbott Fund), Andrew Krivoshik(Abbott (United Kingdom)), Sari H. Enschede(Abbott Fund), Rod Humerickhouse(Abbott (United Kingdom))
Cited by 852Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis